supportive care
[대역어] 보조 치료
[용어속성] Treatment
[용어속성] Treatment
Effect of Tocilizumab vs Standard Care on Clinical Worsening in Patients Hospitalized With COVID-19 Pneumonia: A Randomized Clinical Trial
COVID-19 폐렴으로 입원한 환자의 임상 악화에 대한 Tocilizumab 대 표준 치료의 효과: 무작위 임상 시험
Randomized Controlled Trial
[키워드] 95% CI
age
benefit
blinded
C-reactive protein
causes
clinical
Clinical Center
control arm
control group
coronavirus disease
COVID-19
criteria
death
defined
died
Disease progression
Effect
elevated
EudraCT
evaluate
evaluate the effect
experimental arm
experimental group
Fever
fraction
groups
hospital
Hospitalized
inflammatory phenotype
intensive care
Intention-to-treat analyses
interim analysis
interquartile range
intravenous tocilizumab
Intubated
Invasive mechanical ventilation
Italy
less
majority
male
median
Nasopharyngeal swab
NCT04346355
Open-label
outcome
oxygen
pandemic
Patient
patients hospitalized
patients with COVID-19
placebo-controlled
Pneumonia
polymerase chain
Prospective
protocol
radiologic imaging
randomization
Randomized
randomized clinical trial
randomized patient
receive
Retrospective study
safety profile
second dose
shown
Stage
Standard
standard care
standard care group
Standard of care
Standard therapy
supportive care
the disease
therapy
Tocilizumab
tocilizumab administration
Trial
Two patient
with COVID-19
worsening
[DOI] 10.1001/jamainternmed.2020.6615 PMC 바로가기 [Article Type] Randomized Controlled Trial
[DOI] 10.1001/jamainternmed.2020.6615 PMC 바로가기 [Article Type] Randomized Controlled Trial
Efficacy of Traditional Chinese Medicine, Maxingshigan-Weijing in the management of COVID-19 patients with severe acute respiratory syndrome: A structured summary of a study protocol for a randomized controlled trial
중증 급성 호흡기 증후군이 있는 COVID-19 환자 관리에 대한 중국 전통 의학 Maxingshigan-Weijing의 효능: 무작위 대조 시험을 위한 연구 프로토콜의 구조화된 요약
Letter
[키워드] 1:1
acute respiratory syndrome
acute respiratory syndrome coronavirus
addition
administration
Affiliated Hospital
age
allergic
allergies
anorexia
anti-bacterial
Anti-viral
anticipated
Anxiety
Arm
asked
Asymptomatic
automatically
aversion
blinded
Blinding
Blood tinged
blood tinged sputum
both groups
Care
carried
center
checklist
Chenpi
chest pain
chest X-ray
Chinese
Chinese Clinical Trial Registry
Chinese herbal medicines
clinical
clinical symptom
clinical trials
clinically
Cold
comparator Patients
composed
control group
Controlled trial
coronavirus
cough
COVID-19
COVID-19 patient
criteria
critical patient
critical patients
defined
diarrhea
disease
Diseases
dissemination
distension
Dizziness
dry mouth
dysphoria
effective
Efficacy
element
Eligible patients
ephedra
exclusion criteria
expectoration
female
Fever
Follow-up
four-point scale
Gypsum
H1N1
H1N1 influenza
headache
hematopoietic system
Herba Ephedra
herbal medicine
hospital
IBM
IBM Corp
IMPROVE
improvement
in both group
include
Inclusion
inclusion and exclusion criteria
inclusion criteria
individual
Influenza
Informed consent
Inpatient
Insomnia
Kaplan-Meier method
kidney
Kidney function
lactation
less
liver
log-rank test
malaise
male
management
Maxingshigan-weijing
mechanical ventilation
Medicine
Melon
Mild
mild clinical symptoms
multicenter
multiple organ failure
muscular
nasal
nasal obstruction
nausea
nausea and vomiting
negative test
nucleic acid
number
objective
open
Open-label
oral administration
outcome
participant
Patient
patients
Peach
pharyngalgia
Pneumonia
positive
Pregnancy
previous study
Primary outcome
Professor
proportion
protocol
Radix
random
random allocation
random number generator
randomisation
randomised
Randomized
Randomized controlled trial
randomly divided
receive
recruited
registry
reported
researcher
respiratory
Respiratory failure
respiratory symptom
Sample size
SARS-CoV-2
SARS-CoV-2 nucleic acid
Scoring
second
secondary
Secondary outcomes
Semen
sequence
severe acute respiratory syndrome Coronavirus
severe acute respiratory syndrome coronavirus 2
severity
Shock
Shortness of breath
statistical analysis
Statistical power
Statistics
status
Study protocol
suffering
supplementary material
supportive care
survival
survival time
sweating
Symptom
symptomatic
Symptoms
System
TCM
temperature
test results
the median
therapy
total score
Traditional
Traditional Chinese medicine
treated
Treatment
trial protocol
Trial registration
Trichosanthe
Trichosanthes Kirilowii
university
USA
Version
virus pneumonia
vomiting
website
wheezing
Winter
Withdrawal
[DOI] 10.1186/s13063-020-04970-3 PMC 바로가기 [Article Type] Letter
[DOI] 10.1186/s13063-020-04970-3 PMC 바로가기 [Article Type] Letter
Analyses of abdominal adiposity and metabolic syndrome as risk factors for respiratory distress in COVID-19
Observational Study
[키워드] Adiposity
adjusted
age
analysed
analyses
BMI
Clinical deterioration
Clinical outcome
COVID-19
Deterioration
distress
Gender
Hospital stay
hypertension
independent risk factor
intubation
investigated
Kaplan-Meier
lack
Local
multivariable logistic regression
Netherlands
not differ
obesity
Patient
patients with COVID-19
positive
Prevalence
prospective observational cohort
Prospective Study
provide
respiratory infection
respiratory measurement
respiratory symptom
Result
risk factor
risk stratification
several characteristics
supportive care
syndrome
tested
viral infection
[DOI] 10.1136/bmjresp-2020-000792 PMC 바로가기 [Article Type] Observational Study
[DOI] 10.1136/bmjresp-2020-000792 PMC 바로가기 [Article Type] Observational Study
Effect of Arbidol (Umifenovir) on COVID-19: a randomized controlled trial
COVID-19에 대한 Arbidol(Umifenovir)의 효과: 무작위 대조 시험
Randomized Controlled Trial
[키워드] (Lopinavir/ritonavir
adjusted
Admission
age
Analysis
antiviral drugs
ARB
Arbidol
ARMS
assigned
Chest CT
Clinical improvement
contribute
Corona virus
cough
COVID-19
COVID-19 disease
criteria
determine
diagnosis of COVID-19
duration of hospitalization
Dyspnea
Effect
effective
Efficacy
eligible patient
ESR
examined
Fever
Final
final analysis
followed by
group
groups
Health Organization
hospital
Hospitalization
Hydroxychloroquine
ICU admissions
IHD
Improvements
independent
Kaletra
Laboratory
less
Lopinavir
Lopinavir/ritonavir
male
multicenter design
Multiple linear regression
multiple linear regression analysis
Na level
Open-label
open-label randomized controlled trial
oxygen
oxygen saturation
Patient
patients with COVID-19
peripheral
peripheral oxygen saturation
Peripheral oxygen saturation rate
Primary outcome
Randomized controlled trial
Randomly
recruited
relief
Result
Ritonavir
Sample size
significance level
significantly
supportive care
Symptom
the disease
therapy
time
treatments for COVID-19
Trial registration
two group
two groups
variable
WBC
WHO
World Health Organization
[DOI] 10.1186/s12879-020-05698-w PMC 바로가기 [Article Type] Randomized Controlled Trial
[DOI] 10.1186/s12879-020-05698-w PMC 바로가기 [Article Type] Randomized Controlled Trial
Protease-activated receptor 1 as a potential therapeutic target for COVID-19
Minireview
[키워드] acute respiratory distress
Anticoagulant
anticoagulation
caused
clinical symptom
Coagulation
Coagulopathy
coronavirus
COVID-19
diarrhea
disease
Dizziness
dry cough
Dyspnea
endothelial
Fever
headache
Immune-mediated
include
Inflammation
management
mechanism
Novel coronavirus
pathophysiology
Patient
physiological
poor prognosis
potential therapeutic target
prevalent
proinflammatory cytokines
Protease-activated receptor 1
Proteases
prothrombotic state
receptor
Regulation
Respiratory disease
SARS-CoV-2
severe COVID-19
Spread
supportive care
syndrome
the disease
thrombin
thrombin receptor
thrombosis
tissue damage
Treatment
Vaccine
vomiting
weakness
Wuhan, China
[DOI] 10.1177/1535370220978372 PMC 바로가기 [Article Type] Minireview
[DOI] 10.1177/1535370220978372 PMC 바로가기 [Article Type] Minireview
Clinical characteristics and laboratory biomarkers changes in COVID-19 patients requiring or not intensive or sub-intensive care: a comparative study
집중치료 또는 준집중치료가 필요한 코로나19 환자의 임상적 특성 및 실험실 바이오마커 변화: 비교 연구
Observational Study
[키워드] Admission
aspartate
benefit
C-Reactive-Protein
Care
changes in
Characteristics
chest X-ray
clinical
Clinical characteristics
clinical picture
collected
Comorbidities
Composite
COVID-19
COVID-19 patient
COVID-19 patients
defined
demographic
description
develop
diabete
diabetes
disease
disease severity
dry cough
Factor
Fatality rate
Follow-up
group
had more
Hospitalization
hypertension
ICU
identifying
include
Infectious disease
Infectious diseases
inflammation marker
Intensive
intensive care
Laboratory
laboratory biomarker
laboratory findings
male
median age
neutrophil
neutrophil count
Novel coronavirus
observation
offer
outcome
pathological finding
pathological findings
Patient
Pneumonia
predisposing factors
presence of comorbidity
Primary outcome
radiological
Result
Retrospective study
risk factor
Risk factors
SARS-CoV-2
significantly higher
Sub-intensive care
supplementary material
supportive care
Swab
swabs
transaminase
transfer
transferred
Treatment
two groups
unit
worsening
[DOI] 10.1186/s12879-020-05647-7 PMC 바로가기 [Article Type] Observational Study
[DOI] 10.1186/s12879-020-05647-7 PMC 바로가기 [Article Type] Observational Study
Inflammatory cytokine depletion in severe coronavirus disease 2019 infectious pneumonia A case report
중증 코로나바이러스 감염증 2019 감염성 폐렴에서 염증성 사이토카인 고갈 증례보고
Case Reports
[키워드] acute respiratory syndrome
addition
Administered
Blood
blood gas
blood pressure
branch
Care
Case report
chest imaging
Clinical features
clinical manifestation
convalescent plasma
coronavirus
coronavirus disease
Coronavirus disease 2019
COVID-19
COVID-19 crisis
cytokine
diagnoses
double filtration plasma pheresis
dysfunction
Fever
filtration
healthy
heart rate
high fever
homeostatic
Inflammatory cytokine
inflammatory cytokine depletion
Injury
intravenous
Isolation
male
maternity
non-ICU
nonproductive cough
oropharyngeal swab
parameter
Patient
patients
PCR assay
plasma
Pneumonia
positive
reduce mortality
referred to
Research
RT-PCR assay
Safe
severe acute respiratory syndrome Coronavirus
severe coronavirus disease
severe COVID-19
specimen
SpO2
spontaneous respiration
standard supportive care
supportive care
the patient
therapy
Tocilizumab
transferred
Travel
Viral pneumonia
[DOI] 10.1097/MD.0000000000023449 PMC 바로가기 [Article Type] Case Reports
[DOI] 10.1097/MD.0000000000023449 PMC 바로가기 [Article Type] Case Reports
Pharmacotherapy for Hospitalized Patients with COVID-19: Treatment Patterns by Disease Severity
COVID-19 입원 환자를 위한 약물 요법: 질병 중증도에 따른 치료 패턴
Article
[키워드] 95% confidence interval
Anticoagulant
co-morbidities
coronavirus disease
Coronavirus disease 2019
COVID-19
COVID-19 severity
COVID-19 treatments
defined
determinant
determinants
disease severity
driver
Drivers
dropped
Electronic health record
elevated
evaluate
Fever
FIVE
Health
health record
Healthcare system
hospital
Hospital admission
Hospitalization
Hospitalized
identify
inflammatory biomarkers
intensive care
intensive care unit
Interpretation
Intubated
laboratory-confirmed
Laboratory-confirmed COVID-19
level 1
medication
medications
minute
morbidities
Mortality
non-randomized studies
non-randomized study
Other
outcome
oxygen
oxygen saturation
Patient
patients hospitalized
pattern
pharmacological treatment
pharmacotherapy
predictor
receive
Remdesivir
severity
study period
supplemental oxygen
supportive care
therapeutic
treat
Treatment
[DOI] 10.1007/s40265-020-01424-7 PMC 바로가기 [Article Type] Article
[DOI] 10.1007/s40265-020-01424-7 PMC 바로가기 [Article Type] Article
Pulmonary vascular improvement in severe COVID-19 patients treated with tocilizumab
토실리주맙으로 치료받은 중증 코로나19 환자의 폐혈관 개선
Observational Study
[키워드] addition
alveolar
Alveolar-arterial oxygen gradient
anti-IL-6 receptor
CAR-T
CAR-T cell therapy
Cell therapy
Chest-X ray
clinical
compassionate-use therapies
contrary
controls
coronavirus disease
Coronavirus disease 2019
COVID-19
COVID-19 patient
COVID-19 patients
cytokine
Cytokine release syndrome
develop
explain
Hyperinflammatory syndrome
IL-6
immunomodulatory
Inflammatory marker
inflammatory markers
intensive care
limitations
management
monoclonal antibody
observational study
occur
off-label
oxygen
parameter
Patient
pulmonary
radiologic
receiving
respiratory status
retrospective
severe COVID-19
severe COVID-19 patient
Standard-of-care
suggested
supportive care
therapy
Tocilizumab
tocilizumab -
tocilizumab administration
treated
Treatment
Vascular
Vascular score.
worsened
[DOI] 10.1016/j.imlet.2020.10.009 PMC 바로가기 [Article Type] Observational Study
[DOI] 10.1016/j.imlet.2020.10.009 PMC 바로가기 [Article Type] Observational Study